<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: We developed a granulocyte-macrophage-colony-stimulating factor (GM-CSF) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vaccine for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the effectiveness of the vaccine as a prevention option in a surgical reflux rat model of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A surgical model involving a jejuno-esophagostomy was used to create <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>No carcinogen exposure was utilized </plain></SENT>
<SENT sid="4" pm="."><plain>Cell lines derived from these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were stably passaged in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>GM-CSF-secreting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells were generated using stable transfection </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> rats underwent a total gastrectomy, followed by a jejuno-esophagostomy </plain></SENT>
<SENT sid="7" pm="."><plain>The surgery promoted the reflux of duodenal contents into the esophagus </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> animals were administered either a GM-CSF secreting whole cell vaccine or a phosphate-buffered saline (PBS) placebo injection 4, 6, 14, and 16 weeks post-surgery </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: While 15 of 16 animals in the non-vaccinated placebo group developed <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, 94% (15 of 16), animals in the vaccine group had an incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> of 25% (4 of 16) (p&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> was seen in 100% (16 of 16) of the controls and 83% (13 of 16) of the vaccinated animals </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: A GM-CSF-secreting whole cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vaccine impeded <z:e sem="disease" ids="C0014859" disease_type="Neoplastic Process" abbrv="">esophageal tumor</z:e> growth, but not the development of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, in a clinically relevant surgical reflux model </plain></SENT>
</text></document>